HC Wainwright Boosts Femasys (NASDAQ:FEMY) Price Target to $15.00

Femasys (NASDAQ:FEMY) had its target price hoisted by equities research analysts at HC Wainwright from $12.00 to $15.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Femasys Price Performance

NASDAQ:FEMY opened at $1.60 on Wednesday. Femasys has a one year low of $0.86 and a one year high of $1.84. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. The firm has a market cap of $36.64 million, a price-to-earnings ratio of -1.98 and a beta of -2.85. The firm’s fifty day moving average is $1.36 and its two-hundred day moving average is $1.21.

Institutional Investors Weigh In On Femasys

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in Femasys by 9.2% in the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after purchasing an additional 17,473 shares during the last quarter. XTX Topco Ltd raised its position in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares during the period. Citadel Advisors LLC acquired a new position in shares of Femasys in the fourth quarter worth about $45,000. Jane Street Group LLC acquired a new position in shares of Femasys in the fourth quarter worth about $30,000. Finally, Northern Trust Corp raised its position in shares of Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after acquiring an additional 37,675 shares during the period. 65.27% of the stock is owned by hedge funds and other institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.